Skip to content
Review Open access

Extracellular Vesicle-Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges.

Aug 2026 · European Journal of Haematology · 0 citations · 77 references
Medicine

TL;DR

The biological roles, biomarker potential, therapeutic applications, and methodological challenges of EVs in AML are summarized and the priorities required for their future clinical development are highlighted.

Abstract

Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy in which treatment resistance and relapse remain major causes of mortality. Extracellular vesicles (EVs) contribute to AML progression by mediating communication among leukemic blasts, leukemia stem cells, hematopoietic stem and progenitor cells, stromal and endothelial cells, and immune-cell populations. Experimental studies indicate that AML-associated EVs can remodel the bone marrow niche, suppress normal hematopoiesis, impair antileukemic immune responses, promote leukemic-cell survival, and facilitate drug resistance. Their surface markers and molecular cargo, including proteins, miRNAs, mRNAs, DNA, lipids, and metabolites, have also prompted investigation into their use as liquid-biopsy biomarkers. Candidate EV-based markers include particle abundance, blast-associated antigens, TGF-β1, FLT3-ITD and NPM1 alterations, and several circulating miRNAs. However, most biomarker studies remain small, heterogeneous, and insufficiently compared with established measurable residual disease assays. Therapeutic strategies involving inhibition of EV release or uptake, EV-based immunotherapy, and engineered EVs for drug or RNA delivery are also being explored, but current evidence is predominantly preclinical. Clinical translation is further limited by inconsistent terminology, variable isolation and characterization methods, contamination by non-vesicular particles, and a lack of prospective multicenter validation. This review summarizes the biological roles, biomarker potential, therapeutic applications, and methodological challenges of EVs in AML and highlights the priorities required for their future clinical development.

Read PDF

Similar papers

Review Open access Sep 2026

Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities

An update is provided on the current understanding of EVs in the regulation of hematological cancers, from mechanistic, translational, and therapeutic perspectives and the potential of using EVs as biomarkers and as next-generation immunotherapeutic agents.

Tu-Ya Wang, Jing Fu, Ye Huang et al. · 0 citations
Review Sep 2026

Extracellular vesicle-mediated drug resistance in cancer.

Drug resistance remains a major challenge to successful cancer treatment. Although cell-autonomous genetic, molecular, and cellular modifications have historically been linked to resistance, there is growing evidence that extracellular vesicles (EVs) can promote the intercellular transfer of resistance-associated compo...

Bai-Wei Zhao, Yong-Ming Chen, Hiba Khan et al. · 0 citations
Review Aug 2026

Myeloid-derived suppressor cells in the tumor microenvironment: cellular crosstalk, immunosuppressive effects, and therapeutic targets.

Together, current evidence indicates that MDSCs represent context-dependent therapeutic nodes, while functional reprogramming, spatially resolved profiling, and patient stratification may improve immunotherapy outcomes.

Lisichen Zhu, Hui Liu, Sihan Zhang et al. · 1 citation
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Review Open access Oct 2026

Hypoxia-Driven Extracellular Vesicle Signaling in Lung Cancer Progression, Immune Evasion, and Therapeutic Resistance

Targeting hypoxia-driven EV signaling may suppress tumor progression and improve treatment efficacy, and targeting EV biogenesis or transfer may also help overcome resistance to targeted therapy and immunotherapy.

Dordaneh Mirbabaei Ghafghazi, P. Klentrou, Siu-Kwan Sze et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.